Cliff Asness's IONS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 6,815 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $438,749, representing 0.00% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2016, adding 1.47 M shares. Largest reduction occurred in Q3 2016, reducing 1.45 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2015 | +614,086 | New Buy | 614,086 | $61.93 |
| Q1 2016 | -220,851 | Reduce 35.96% | 393,235 | $40.50 |
| Q2 2016 | +1.47 M | Add 372.55% | 1.86 M | $23.29 |
| Q3 2016 | -1.45 M | Reduce 78.07% | 407,582 | $36.64 |
| Q4 2016 | -407,582 | Sold Out | 407,582 | $0.00 |
| Q3 2017 | +17,857 | New Buy | 17,857 | $50.68 |
| Q4 2017 | +370 | Add 2.07% | 18,227 | $50.31 |
| Q1 2018 | -813 | Reduce 4.46% | 17,414 | $44.10 |
| Q2 2018 | +27 | Add 0.16% | 17,441 | $41.68 |
| Q3 2018 | -4,835 | Reduce 27.72% | 12,606 | $51.56 |
| Q4 2018 | -2,959 | Reduce 23.47% | 9,647 | $54.11 |
| Q1 2019 | +402,227 | Add 4169.45% | 411,874 | $80.18 |
| Q2 2019 | +92,068 | Add 22.35% | 503,942 | $64.27 |
| Q3 2019 | -479,149 | Reduce 95.08% | 24,793 | $59.90 |
| Q4 2019 | -10,652 | Reduce 42.96% | 14,141 | $60.25 |
| Q1 2020 | -8,236 | Reduce 58.24% | 5,905 | $47.25 |
| Q2 2020 | -1,514 | Reduce 25.64% | 4,391 | $58.98 |
| Q3 2020 | -4,391 | Sold Out | 4,391 | $0.00 |
| Q2 2021 | +13,434 | New Buy | 13,434 | $39.30 |
| Q3 2021 | -13,434 | Sold Out | 13,434 | $0.00 |
| Q3 2022 | +7,710 | New Buy | 7,710 | $44.23 |
| Q4 2022 | -141 | Reduce 1.83% | 7,569 | $37.26 |
| Q1 2023 | -7,569 | Sold Out | 7,569 | $0.00 |
| Q4 2023 | +4,300 | New Buy | 4,300 | $49.84 |
| Q1 2024 | -4,300 | Sold Out | 4,300 | $0.00 |
| Q3 2025 | +6,815 | New Buy | 6,815 | $64.38 |
Cliff Asness's Ionis Pharmaceuticals Investment FAQs
Cliff Asness first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 614,086 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Ionis Pharmaceuticals, Inc. (IONS) for 40 quarters since Q4 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q2 2016, adding 1,858,239 shares worth $43.28 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 6,815 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $438,749. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 1,858,239 shares, as reported at the end of Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.